

## REMARKS

Upon entry of the above amendment, claims 1-27 and 29-30 will be pending in the application. Applicants have withdrawn claims 6-27 and 29-30 from examination in response to restriction requirement and request rejoinder if claims 1-5 are found allowable.

### Restriction/Election

The Examiner has set forth a restriction requirement.

Group I, claims 1-6, are drawn to compounds, process of making and composition.

Group II, claims 7-31, are drawn to methods of using compounds.

Applicants respectfully note that claims 1-5 are drawn to compounds, process of making and compositions, and claims 6-31 are drawn to a method of using compounds. The Examiner included of claim 6 in Group I and did not including the subsequent dependent claim. Applicants feel this was a typographical error. Therefore, Applicants response understands Group I to be claims 1-5.

Applicants respectfully assert that the compounds of Group I are the special technical feature that make the methods of Group II. The Examiner has not set forth any argument supported by prior art that the compounds of Group I are not patentable, therefore according to PCT Rule 13.1 the Examiner must examine the complete claim set. Applicants respectfully request withdrawal of the restriction requirement.

To be responsive, Applicants elect Group I claims 1-5. Applicants respectfully request that method claims 6-27 and 29-30 be rejoined when claims 1-5 are indicated as allowable, which is the present U.S. Patent law.

Applicants elect the compound of Example 1, which is the subject matter of claim 4. Applicants do not understand the A-D restriction. Applicants request that the Examiner use the elected species as a guide to any further restriction.

Conclusion

Applicants have addressed each and every issue set forth by the Examiner. Applicants respectfully submit that the present application is in good condition for allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-4125.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 19-0134 for any additional fees under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-4125

  
Mark W. Milstead  
Attorney for Applicant  
Reg. No. 45,825

Date: 11/2/07